The global market for Type 1 Diabetes Drugs was valued at US$ 32580 million in the year 2024 and is projected to reach a revised size of US$ 59430 million by 2031, growing at a CAGR of 9.1% during the forecast period.

Type 1 Diabetes Drugs Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Type 1 Diabetes Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Type 1 Diabetes Drugs.

The Type 1 Diabetes Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Type 1 Diabetes Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Type 1 Diabetes Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Type 1 Diabetes Drugs Market Report

Report Metric	Details
Report Name	Type 1 Diabetes Drugs Market
Accounted market size in year	US$ 32580 million
Forecasted market size in 2031	US$ 59430 million
CAGR	9.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Insulins Others
Segment by Application	Drugstore Hospital Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Sanofi, Eli Lily, Adocia, Astellas Pharma, AstraZeneca, BHV Pharma, Biodel, Boehringer Ingelheim, Diamyd Therapeutics AB
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Type 1 Diabetes Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Type 1 Diabetes Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Type 1 Diabetes Drugs Market growing?

Ans: The Type 1 Diabetes Drugs Market witnessing a CAGR of 9.1% during the forecast period 2025-2031.

What is the Type 1 Diabetes Drugs Market size in 2031?

Ans: The Type 1 Diabetes Drugs Market size in 2031 will be US$ 59430 million.

Who are the main players in the Type 1 Diabetes Drugs Market report?

Ans: The main players in the Type 1 Diabetes Drugs Market are Novo Nordisk, Sanofi, Eli Lily, Adocia, Astellas Pharma, AstraZeneca, BHV Pharma, Biodel, Boehringer Ingelheim, Diamyd Therapeutics AB

What are the Application segmentation covered in the Type 1 Diabetes Drugs Market report?

Ans: The Applications covered in the Type 1 Diabetes Drugs Market report are Drugstore, Hospital, Others

What are the Type segmentation covered in the Type 1 Diabetes Drugs Market report?

Ans: The Types covered in the Type 1 Diabetes Drugs Market report are Insulins, Others

1 Type 1 Diabetes Drugs Market Overview

1.1 Product Definition

1.2 Type 1 Diabetes Drugs by Type

1.2.1 Global Type 1 Diabetes Drugs Market Value Comparison by Type (2024 VS 2031)

1.2.2 Insulins

1.2.3 Others

1.3 Type 1 Diabetes Drugs by Application

1.3.1 Global Type 1 Diabetes Drugs Market Value by Application (2024 VS 2031)

1.3.2 Drugstore

1.3.3 Hospital

1.3.4 Others

1.4 Global Type 1 Diabetes Drugs Market Size Estimates and Forecasts

1.4.1 Global Type 1 Diabetes Drugs Revenue 2020-2031

1.4.2 Global Type 1 Diabetes Drugs Sales 2020-2031

1.4.3 Global Type 1 Diabetes Drugs Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Type 1 Diabetes Drugs Market Competition by Manufacturers

2.1 Global Type 1 Diabetes Drugs Sales Market Share by Manufacturers (2020-2025)

2.2 Global Type 1 Diabetes Drugs Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Type 1 Diabetes Drugs Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Type 1 Diabetes Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Type 1 Diabetes Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Type 1 Diabetes Drugs, Product Type & Application

2.7 Global Key Manufacturers of Type 1 Diabetes Drugs, Date of Enter into This Industry

2.8 Global Type 1 Diabetes Drugs Market Competitive Situation and Trends

2.8.1 Global Type 1 Diabetes Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Type 1 Diabetes Drugs Players Market Share by Revenue

2.8.3 Global Type 1 Diabetes Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Type 1 Diabetes Drugs Market Scenario by Region

3.1 Global Type 1 Diabetes Drugs Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Type 1 Diabetes Drugs Sales by Region: 2020-2031

3.2.1 Global Type 1 Diabetes Drugs Sales by Region: 2020-2025

3.2.2 Global Type 1 Diabetes Drugs Sales by Region: 2026-2031

3.3 Global Type 1 Diabetes Drugs Revenue by Region: 2020-2031

3.3.1 Global Type 1 Diabetes Drugs Revenue by Region: 2020-2025

3.3.2 Global Type 1 Diabetes Drugs Revenue by Region: 2026-2031

3.4 North America Type 1 Diabetes Drugs Market Facts & Figures by Country

3.4.1 North America Type 1 Diabetes Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Type 1 Diabetes Drugs Sales by Country (2020-2031)

3.4.3 North America Type 1 Diabetes Drugs Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Type 1 Diabetes Drugs Market Facts & Figures by Country

3.5.1 Europe Type 1 Diabetes Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Type 1 Diabetes Drugs Sales by Country (2020-2031)

3.5.3 Europe Type 1 Diabetes Drugs Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Type 1 Diabetes Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Type 1 Diabetes Drugs Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Type 1 Diabetes Drugs Sales by Region (2020-2031)

3.6.3 Asia Pacific Type 1 Diabetes Drugs Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Type 1 Diabetes Drugs Market Facts & Figures by Country

3.7.1 Latin America Type 1 Diabetes Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Type 1 Diabetes Drugs Sales by Country (2020-2031)

3.7.3 Latin America Type 1 Diabetes Drugs Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Type 1 Diabetes Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Type 1 Diabetes Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Type 1 Diabetes Drugs Sales by Country (2020-2031)

3.8.3 Middle East and Africa Type 1 Diabetes Drugs Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Type 1 Diabetes Drugs Sales by Type (2020-2031)

4.1.1 Global Type 1 Diabetes Drugs Sales by Type (2020-2025)

4.1.2 Global Type 1 Diabetes Drugs Sales by Type (2026-2031)

4.1.3 Global Type 1 Diabetes Drugs Sales Market Share by Type (2020-2031)

4.2 Global Type 1 Diabetes Drugs Revenue by Type (2020-2031)

4.2.1 Global Type 1 Diabetes Drugs Revenue by Type (2020-2025)

4.2.2 Global Type 1 Diabetes Drugs Revenue by Type (2026-2031)

4.2.3 Global Type 1 Diabetes Drugs Revenue Market Share by Type (2020-2031)

4.3 Global Type 1 Diabetes Drugs Price by Type (2020-2031)

5 Segment by Application

5.1 Global Type 1 Diabetes Drugs Sales by Application (2020-2031)

5.1.1 Global Type 1 Diabetes Drugs Sales by Application (2020-2025)

5.1.2 Global Type 1 Diabetes Drugs Sales by Application (2026-2031)

5.1.3 Global Type 1 Diabetes Drugs Sales Market Share by Application (2020-2031)

5.2 Global Type 1 Diabetes Drugs Revenue by Application (2020-2031)

5.2.1 Global Type 1 Diabetes Drugs Revenue by Application (2020-2025)

5.2.2 Global Type 1 Diabetes Drugs Revenue by Application (2026-2031)

5.2.3 Global Type 1 Diabetes Drugs Revenue Market Share by Application (2020-2031)

5.3 Global Type 1 Diabetes Drugs Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Novo Nordisk Type 1 Diabetes Drugs Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Company Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Sanofi Type 1 Diabetes Drugs Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 Eli Lily

6.3.1 Eli Lily Company Information

6.3.2 Eli Lily Description and Business Overview

6.3.3 Eli Lily Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Eli Lily Type 1 Diabetes Drugs Product Portfolio

6.3.5 Eli Lily Recent Developments/Updates

6.4 Adocia

6.4.1 Adocia Company Information

6.4.2 Adocia Description and Business Overview

6.4.3 Adocia Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Adocia Type 1 Diabetes Drugs Product Portfolio

6.4.5 Adocia Recent Developments/Updates

6.5 Astellas Pharma

6.5.1 Astellas Pharma Company Information

6.5.2 Astellas Pharma Description and Business Overview

6.5.3 Astellas Pharma Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Astellas Pharma Type 1 Diabetes Drugs Product Portfolio

6.5.5 Astellas Pharma Recent Developments/Updates

6.6 AstraZeneca

6.6.1 AstraZeneca Company Information

6.6.2 AstraZeneca Description and Business Overview

6.6.3 AstraZeneca Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.6.4 AstraZeneca Type 1 Diabetes Drugs Product Portfolio

6.6.5 AstraZeneca Recent Developments/Updates

6.7 BHV Pharma

6.7.1 BHV Pharma Company Information

6.7.2 BHV Pharma Description and Business Overview

6.7.3 BHV Pharma Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.7.4 BHV Pharma Type 1 Diabetes Drugs Product Portfolio

6.7.5 BHV Pharma Recent Developments/Updates

6.8 Biodel

6.8.1 Biodel Company Information

6.8.2 Biodel Description and Business Overview

6.8.3 Biodel Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Biodel Type 1 Diabetes Drugs Product Portfolio

6.8.5 Biodel Recent Developments/Updates

6.9 Boehringer Ingelheim

6.9.1 Boehringer Ingelheim Company Information

6.9.2 Boehringer Ingelheim Description and Business Overview

6.9.3 Boehringer Ingelheim Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Boehringer Ingelheim Type 1 Diabetes Drugs Product Portfolio

6.9.5 Boehringer Ingelheim Recent Developments/Updates

6.10 Diamyd Therapeutics AB

6.10.1 Diamyd Therapeutics AB Company Information

6.10.2 Diamyd Therapeutics AB Description and Business Overview

6.10.3 Diamyd Therapeutics AB Type 1 Diabetes Drugs Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Diamyd Therapeutics AB Type 1 Diabetes Drugs Product Portfolio

6.10.5 Diamyd Therapeutics AB Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Type 1 Diabetes Drugs Industry Chain Analysis

7.2 Type 1 Diabetes Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Type 1 Diabetes Drugs Production Mode & Process Analysis

7.4 Type 1 Diabetes Drugs Sales and Marketing

7.4.1 Type 1 Diabetes Drugs Sales Channels

7.4.2 Type 1 Diabetes Drugs Distributors

7.5 Type 1 Diabetes Drugs Customer Analysis

8 Type 1 Diabetes Drugs Market Dynamics

8.1 Type 1 Diabetes Drugs Industry Trends

8.2 Type 1 Diabetes Drugs Market Drivers

8.3 Type 1 Diabetes Drugs Market Challenges

8.4 Type 1 Diabetes Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Diamyd Therapeutics AB

List of Tables

Table 1. Global Type 1 Diabetes Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Type 1 Diabetes Drugs Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Type 1 Diabetes Drugs Market Competitive Situation by Manufacturers in 2024

Table 4. Global Type 1 Diabetes Drugs Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Type 1 Diabetes Drugs Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Type 1 Diabetes Drugs Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Type 1 Diabetes Drugs Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Type 1 Diabetes Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Type 1 Diabetes Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Type 1 Diabetes Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Type 1 Diabetes Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Type 1 Diabetes Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Type 1 Diabetes Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Type 1 Diabetes Drugs as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Type 1 Diabetes Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Type 1 Diabetes Drugs Sales by Region (2020-2025) & (K Units)

Table 18. Global Type 1 Diabetes Drugs Sales Market Share by Region (2020-2025)

Table 19. Global Type 1 Diabetes Drugs Sales by Region (2026-2031) & (K Units)

Table 20. Global Type 1 Diabetes Drugs Sales Market Share by Region (2026-2031)

Table 21. Global Type 1 Diabetes Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Type 1 Diabetes Drugs Revenue Market Share by Region (2020-2025)

Table 23. Global Type 1 Diabetes Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Type 1 Diabetes Drugs Revenue Market Share by Region (2026-2031)

Table 25. North America Type 1 Diabetes Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Type 1 Diabetes Drugs Sales by Country (2020-2025) & (K Units)

Table 27. North America Type 1 Diabetes Drugs Sales by Country (2026-2031) & (K Units)

Table 28. North America Type 1 Diabetes Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Type 1 Diabetes Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Type 1 Diabetes Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Type 1 Diabetes Drugs Sales by Country (2020-2025) & (K Units)

Table 32. Europe Type 1 Diabetes Drugs Sales by Country (2026-2031) & (K Units)

Table 33. Europe Type 1 Diabetes Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Type 1 Diabetes Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Type 1 Diabetes Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Type 1 Diabetes Drugs Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Type 1 Diabetes Drugs Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Type 1 Diabetes Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Type 1 Diabetes Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Type 1 Diabetes Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Type 1 Diabetes Drugs Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Type 1 Diabetes Drugs Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Type 1 Diabetes Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Type 1 Diabetes Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Type 1 Diabetes Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Type 1 Diabetes Drugs Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Type 1 Diabetes Drugs Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Type 1 Diabetes Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Type 1 Diabetes Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Type 1 Diabetes Drugs Sales (K Units) by Type (2020-2025)

Table 51. Global Type 1 Diabetes Drugs Sales (K Units) by Type (2026-2031)

Table 52. Global Type 1 Diabetes Drugs Sales Market Share by Type (2020-2025)

Table 53. Global Type 1 Diabetes Drugs Sales Market Share by Type (2026-2031)

Table 54. Global Type 1 Diabetes Drugs Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Type 1 Diabetes Drugs Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Type 1 Diabetes Drugs Revenue Market Share by Type (2020-2025)

Table 57. Global Type 1 Diabetes Drugs Revenue Market Share by Type (2026-2031)

Table 58. Global Type 1 Diabetes Drugs Price (USD/Unit) by Type (2020-2025)

Table 59. Global Type 1 Diabetes Drugs Price (USD/Unit) by Type (2026-2031)

Table 60. Global Type 1 Diabetes Drugs Sales (K Units) by Application (2020-2025)

Table 61. Global Type 1 Diabetes Drugs Sales (K Units) by Application (2026-2031)

Table 62. Global Type 1 Diabetes Drugs Sales Market Share by Application (2020-2025)

Table 63. Global Type 1 Diabetes Drugs Sales Market Share by Application (2026-2031)

Table 64. Global Type 1 Diabetes Drugs Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Type 1 Diabetes Drugs Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Type 1 Diabetes Drugs Revenue Market Share by Application (2020-2025)

Table 67. Global Type 1 Diabetes Drugs Revenue Market Share by Application (2026-2031)

Table 68. Global Type 1 Diabetes Drugs Price (USD/Unit) by Application (2020-2025)

Table 69. Global Type 1 Diabetes Drugs Price (USD/Unit) by Application (2026-2031)

Table 70. Novo Nordisk Company Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Novo Nordisk Type 1 Diabetes Drugs Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. Sanofi Company Information

Table 76. Sanofi Description and Business Overview

Table 77. Sanofi Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Sanofi Type 1 Diabetes Drugs Product

Table 79. Sanofi Recent Developments/Updates

Table 80. Eli Lily Company Information

Table 81. Eli Lily Description and Business Overview

Table 82. Eli Lily Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Eli Lily Type 1 Diabetes Drugs Product

Table 84. Eli Lily Recent Developments/Updates

Table 85. Adocia Company Information

Table 86. Adocia Description and Business Overview

Table 87. Adocia Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Adocia Type 1 Diabetes Drugs Product

Table 89. Adocia Recent Developments/Updates

Table 90. Astellas Pharma Company Information

Table 91. Astellas Pharma Description and Business Overview

Table 92. Astellas Pharma Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Astellas Pharma Type 1 Diabetes Drugs Product

Table 94. Astellas Pharma Recent Developments/Updates

Table 95. AstraZeneca Company Information

Table 96. AstraZeneca Description and Business Overview

Table 97. AstraZeneca Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. AstraZeneca Type 1 Diabetes Drugs Product

Table 99. AstraZeneca Recent Developments/Updates

Table 100. BHV Pharma Company Information

Table 101. BHV Pharma Description and Business Overview

Table 102. BHV Pharma Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. BHV Pharma Type 1 Diabetes Drugs Product

Table 104. BHV Pharma Recent Developments/Updates

Table 105. Biodel Company Information

Table 106. Biodel Description and Business Overview

Table 107. Biodel Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Biodel Type 1 Diabetes Drugs Product

Table 109. Biodel Recent Developments/Updates

Table 110. Boehringer Ingelheim Company Information

Table 111. Boehringer Ingelheim Description and Business Overview

Table 112. Boehringer Ingelheim Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Boehringer Ingelheim Type 1 Diabetes Drugs Product

Table 114. Boehringer Ingelheim Recent Developments/Updates

Table 115. Diamyd Therapeutics AB Company Information

Table 116. Diamyd Therapeutics AB Description and Business Overview

Table 117. Diamyd Therapeutics AB Type 1 Diabetes Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Diamyd Therapeutics AB Type 1 Diabetes Drugs Product

Table 119. Diamyd Therapeutics AB Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Type 1 Diabetes Drugs Distributors List

Table 123. Type 1 Diabetes Drugs Customers List

Table 124. Type 1 Diabetes Drugs Market Trends

Table 125. Type 1 Diabetes Drugs Market Drivers

Table 126. Type 1 Diabetes Drugs Market Challenges

Table 127. Type 1 Diabetes Drugs Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Type 1 Diabetes Drugs

Figure 2. Global Type 1 Diabetes Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Type 1 Diabetes Drugs Market Share by Type: 2024 & 2031

Figure 4. Insulins Product Picture

Figure 5. Others Product Picture

Figure 6. Global Type 1 Diabetes Drugs Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Type 1 Diabetes Drugs Market Share by Application: 2024 & 2031

Figure 8. Drugstore

Figure 9. Hospital

Figure 10. Others

Figure 11. Global Type 1 Diabetes Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Type 1 Diabetes Drugs Market Size (2020-2031) & (US$ Million)

Figure 13. Global Type 1 Diabetes Drugs Sales (2020-2031) & (K Units)

Figure 14. Global Type 1 Diabetes Drugs Average Price (USD/Unit) & (2020-2031)

Figure 15. Type 1 Diabetes Drugs Report Years Considered

Figure 16. Type 1 Diabetes Drugs Sales Share by Manufacturers in 2024

Figure 17. Global Type 1 Diabetes Drugs Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Type 1 Diabetes Drugs Players: Market Share by Revenue in Type 1 Diabetes Drugs in 2024

Figure 19. Type 1 Diabetes Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Type 1 Diabetes Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Type 1 Diabetes Drugs Sales Market Share by Country (2020-2031)

Figure 22. North America Type 1 Diabetes Drugs Revenue Market Share by Country (2020-2031)

Figure 23. U.S. Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Type 1 Diabetes Drugs Sales Market Share by Country (2020-2031)

Figure 26. Europe Type 1 Diabetes Drugs Revenue Market Share by Country (2020-2031)

Figure 27. Germany Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Type 1 Diabetes Drugs Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Type 1 Diabetes Drugs Revenue Market Share by Region (2020-2031)

Figure 34. China Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Taiwan Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Indonesia Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Thailand Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Malaysia Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Philippines Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Type 1 Diabetes Drugs Sales Market Share by Country (2020-2031)

Figure 45. Latin America Type 1 Diabetes Drugs Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Type 1 Diabetes Drugs Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Type 1 Diabetes Drugs Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. U.A.E Type 1 Diabetes Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Type 1 Diabetes Drugs by Type (2020-2031)

Figure 55. Global Revenue Market Share of Type 1 Diabetes Drugs by Type (2020-2031)

Figure 56. Global Type 1 Diabetes Drugs Price (USD/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Type 1 Diabetes Drugs by Application (2020-2031)

Figure 58. Global Revenue Market Share of Type 1 Diabetes Drugs by Application (2020-2031)

Figure 59. Global Type 1 Diabetes Drugs Price (USD/Unit) by Application (2020-2031)

Figure 60. Type 1 Diabetes Drugs Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions